Ken Griffin United Therapeutics Corp Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in United Therapeutics Corp stock. As of the latest transaction made, Citadel Advisors LLC holds 29,500 shares of UTHR stock, worth $10.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

29,500

Previous 31,800 7.23%

Holding current value

$10.6 Million

Previous $10.1 Million 4.36%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$210.76 - $249.51 $135 Million - $160 Million	641,414 Added 823.41%	719,311 $165 Million
Q4 2023 Feb 14, 2024	BUY	$214.88 - $256.94 $12.2 Million - $14.6 Million	56,825 Added 269.67%	77,897 $17.1 Million
Q3 2023 Nov 14, 2023	SELL	$211.82 - $248.24 $4.71 Million - $5.52 Million	-22,252 Reduced 51.36%	21,072 $4.76 Million
Q2 2023 Aug 14, 2023	SELL	$205.19 - $232.99 $2.21 Million - $2.51 Million	-10,776 Reduced 19.92%	43,324 $9.56 Million
Q1 2023 May 15, 2023	SELL	$212.99 - $276.17 $57.7 Million - $74.8 Million	-270,831 Reduced 83.35%	54,100 $12.1 Million
Q4 2022 Feb 14, 2023	SELL	$205.95 - $280.43 $59.6 Million - $81.2 Million	-289,581 Reduced 47.12%	324,931 $90.4 Million
Q3 2022 Nov 14, 2022	BUY	$203.3 - $244.17 $113 Million - $136 Million	555,159 Added 935.35%	614,512 $129 Million
Q2 2022 Aug 15, 2022	SELL	$174.81 - $241.14 $30.4 Million - $42 Million	-174,171 Reduced 74.58%	59,353 $14 Million
Q1 2022 May 16, 2022	BUY	$166.16 - $213.96 $19 Million - $24.5 Million	114,607 Added 96.38%	233,524 $41.9 Million
Q4 2021 Feb 14, 2022	SELL	$184.32 - $216.08 $37.3 Million - $43.8 Million	-202,582 Reduced 63.01%	118,917 $25.7 Million
Q3 2021 Nov 15, 2021	BUY	$179.86 - $214.88 $14.8 Million - $17.7 Million	82,426 Added 34.48%	321,499 $59.3 Million
Q2 2021 Aug 16, 2021	SELL	$170.47 - $211.93 $13.7 Million - $17.1 Million	-80,538 Reduced 25.2%	239,073 $42.9 Million
Q1 2021 May 17, 2021	SELL	$153.94 - $174.85 $63.5 Million - $72.1 Million	-412,397 Reduced 56.34%	319,611 $53.5 Million
Q4 2020 Feb 16, 2021	BUY	$101.87 - $151.79 $10.5 Million - $15.7 Million	103,306 Added 16.43%	732,008 $111 Million
Q3 2020 Nov 16, 2020	SELL	$99.9 - $121.13 $25.1 Million - $30.4 Million	-250,889 Reduced 28.52%	628,702 $63.5 Million
Q2 2020 Aug 14, 2020	SELL	$92.74 - $125.82 $48.7 Million - $66.1 Million	-525,343 Reduced 37.39%	879,591 $106 Million
Q1 2020 May 15, 2020	BUY	$79.39 - $115.35 $13.8 Million - $20 Million	173,427 Added 14.08%	1,404,934 $133 Million
Q4 2019 Feb 14, 2020	SELL	$78.31 - $95.34 $17.9 Million - $21.7 Million	-228,098 Reduced 15.63%	1,231,507 $108 Million
Q3 2019 Nov 14, 2019	BUY	$74.85 - $85.99 $57.8 Million - $66.4 Million	771,704 Added 112.18%	1,459,605 $116 Million
Q2 2019 Aug 14, 2019	BUY	$76.06 - $120.81 $52 Million - $82.5 Million	683,034 Added 14033.98%	687,901 $53.7 Million
Q1 2019 May 15, 2019	SELL	$107.15 - $126.84 $2.32 Million - $2.75 Million	-21,669 Reduced 81.66%	4,867 $0
Q4 2018 Feb 14, 2019	SELL	$101.4 - $128.73 $7.54 Million - $9.58 Million	-74,392 Reduced 73.71%	26,536 $2.89 Million
Q3 2018 Nov 13, 2018	BUY	$113.81 - $129.46 $1.19 Million - $1.36 Million	10,481 Added 11.59%	100,928 $0
Q2 2018 Aug 10, 2018	SELL	$101.14 - $118.31 $6.15 Million - $7.2 Million	-60,851 Reduced 40.22%	90,447 $0
Q1 2018 May 11, 2018	BUY	$107.21 - $151.94 $13.9 Million - $19.8 Million	130,068 Added 612.66%	151,298 $17 Million
Q4 2017 Feb 09, 2018	SELL	$118.58 - $151.28 $6.66 Million - $8.5 Million	-56,198 Reduced 72.58%	21,230 $3.14 Million
Q3 2017 Nov 09, 2017	BUY	$114.6 - $136.81 $8.87 Million - $10.6 Million	77,428	77,428 $9.07 Million

Others Institutions Holding UTHR

# of Institutions

671

Shares Held

42.3M

Call Options Held

194K

Put Options Held

295K

View Full List

About UNITED THERAPEUTICS Corp

Ticker UTHR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,516,300
Market Cap $16.4B
Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...

More about UTHR

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account